<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00291811</url>
  </required_header>
  <id_info>
    <org_study_id>AMD3100-CUP001</org_study_id>
    <nct_id>NCT00291811</nct_id>
  </id_info>
  <brief_title>Access Program for Use of AMD3100 to Increase Peripheral Blood Stem Cells for Transplantation in Patients Who Have Failed Standard Therapy Stem Cell Mobilization</brief_title>
  <acronym>CUP</acronym>
  <official_title>Compassionate Use Protocol for the Use of AMD3100 to Mobilize Peripheral Blood Stem Cells for Collection and Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The purpose of this program is to provide access to AMD3100 for patients who would benefit&#xD;
      from an autologous stem cell transplant but who have either previously failed to collect&#xD;
      enough cells for transplant following standard therapy or are not considered by their&#xD;
      physician to have a reasonable chance of collecting enough cells for transplant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this program is to provide access to AMD3100 for patients who would benefit&#xD;
      from an autologous stem cell transplant but who have either previously failed to collect&#xD;
      enough cells for transplant following standard therapy or are not considered by their&#xD;
      physician to have a reasonable chance of collecting enough cells for transplant.&#xD;
&#xD;
      Compassionate use is a way to provide experimental treatment to a patient who is not eligible&#xD;
      to receive that therapy in a clinical trial, but who has a serious or life-threatening&#xD;
      illness for which other treatments are not available.&#xD;
&#xD;
      Peripheral blood stem cells are obtained by apheresis following a stem cell mobilization&#xD;
      regimen. The standard of care regimen for stem cell mobilization includes a growth factor,&#xD;
      G-CSF. AMD3100 is given in addition to G-CSF prior to each apheresis session. If enough&#xD;
      peripheral blood stem cells for transplant are collected, the patient is treated with high&#xD;
      dose chemotherapy in preparation for transplant and is transplanted with cells obtained from&#xD;
      the AMD3100 and G-CSF regimen. Patients are followed for safety and transplant outcomes for&#xD;
      up to 12 months after transplant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Approved for marketing</overall_status>
  <start_date>October 2003</start_date>
  <study_type>Expanded Access</study_type>
  <condition>Autologous Stem Cell Transplant</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMD3100 + G-CSF</intervention_name>
    <description>Subcutaneous injection of 240 mcg/kg on the evening prior to each apheresis session</description>
    <other_name>Plerixafor(injection)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient is eligible for autologous transplant&#xD;
&#xD;
          -  Patient has failed previous conventional therapies for stem cell collection, or is not&#xD;
             considered by the physician to have a reasonable chance of collecting enough cells for&#xD;
             transplant&#xD;
&#xD;
          -  Patient has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          -  Patient has recovered from all acute toxic effects of prior chemotherapy&#xD;
&#xD;
          -  Patient has white blood cell count greater than 2.5 x 10^9 cells/L&#xD;
&#xD;
          -  Patient has absolute neutrophil count (ANC) greater than 1.5 x 10^9 cells/L&#xD;
&#xD;
          -  Patient has platelet count greater than 85 x 10^9 cells/L&#xD;
&#xD;
          -  Patient has serum creatinine less than or equal to 1.5 mg/dL&#xD;
&#xD;
          -  Patient has creatinine clearance greater than 60 mL/min&#xD;
&#xD;
          -  Patient has liver function tests less than 2x upper limit of normal&#xD;
&#xD;
          -  Patient has left ventricle ejection fraction greater than 45%&#xD;
&#xD;
          -  Patient has forced expiratory volume in 1 second (FEV1) greater than 60% of predicted&#xD;
             or diffusing capacity of lung carbon monoxide (DLCO) and greater than or equal to 45%&#xD;
             of predicted&#xD;
&#xD;
          -  Patient has no active infection of hepatitis B or C&#xD;
&#xD;
          -  Patient is negative for HIV&#xD;
&#xD;
          -  Patient has signed informed consent&#xD;
&#xD;
          -  Women of child bearing potential agree to use an approved form of contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with leukemia (Note: Patients with multiple myeloma must be evaluated for&#xD;
             plasma cells or blasts within 24 hours prior to the first dose of AMD3100)&#xD;
&#xD;
          -  Patient has an existing condition which, in the view of the Investigator, renders the&#xD;
             patient at high risk from treatment complications&#xD;
&#xD;
          -  Patient has a residual acute medical condition resulting from prior chemotherapy&#xD;
&#xD;
          -  Patient has brain metastases or carcinomatous meningitis&#xD;
&#xD;
          -  Patient has an acute infection&#xD;
&#xD;
          -  Patient has a fever (temperature greater than 38 degrees C/100.4 degrees F)&#xD;
&#xD;
          -  Patient has hypercalcaemia greater than 1 mg/dL above the upper limit of normal&#xD;
&#xD;
          -  Female patient has positive pregnancy test&#xD;
&#xD;
          -  Female patient is lactating&#xD;
&#xD;
          -  Patient is of child-bearing potential and is unwilling to use adequate birth control&#xD;
&#xD;
          -  Patients with actual body weight exceeding 175% of their ideal body weight&#xD;
&#xD;
          -  Patients who previously received experimental therapy within 4 weeks of enrolling in&#xD;
             this protocol or who are currently enrolled in another experimental protocol&#xD;
&#xD;
          -  Patients who experience a deterioration in health between the time of enrollment and&#xD;
             transplant (such that they no longer meet entry criteria) may be removed from study at&#xD;
             the discretion of the treating physician, principal Investigator, or Sponsor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>78 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Genzyme, a Sanofi Company</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>February 13, 2006</study_first_submitted>
  <study_first_submitted_qc>February 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2006</study_first_posted>
  <last_update_submitted>February 10, 2014</last_update_submitted>
  <last_update_submitted_qc>February 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AMD3100</keyword>
  <keyword>G-CSF</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plerixafor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

